Hepatoprotection and hepatotoxicity of Heshouwu, a Chinese medicinal herb: context of the paradoxical effect
作者单位：Laboratory of Chinese Herbal Pharmacology Oncology Center Renmin Hospital Hubei University of Medicine Biomedical Research Institute Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine School of Chinese Medicine the University of Hong Kong
会议名称：《第二届临床中药学大会》
会议日期：2018年
学科分类：1008[医学-中药学(可授医学、理学学位)] 1006[医学-中西医结合] 100602[医学-中西医结合临床] 10[医学]
基 金：financially supported by the Young Scientist Innovation Team Project of Hubei Colleges(T201510) the Hubei Province Health and Family Planning Scientific Research Project(WJ2017Z023) the Open Project of Hubei Key Laboratory of Wudang Local Chinese Medicine Research,Hubei University of Medicine(WDCM001) the Key Discipline Project of Hubei University of Medicine and the Foundation for Innovative Research Team of Hubei University of Medicine(2014CXG03) the Key Discipline Project of Hubei Province(2014XKJSXJ18)
关 键 词：Polygoni Multiflori Radix hepatoprotection hepatotoxicity
摘 要：Heshouwu（Polygonum multiflorum Thunb.） has been a common Chinese medicine and a folk Taoist medicine for over a thousand years. There are two drug forms, Shengshouwu（Polygoni Multiflori Radix） and Zhiheshouwu（Polygoni Multiflori Radix Prapaerata） in the Chinese Pharmacopoeia. In this review, we retrieved articles with such keywords as Heshouwu, liver protection and liver toxicity in the databases of PubMed and the China National Knowledge Infrastructure（CNKI）. Hepatoprotection and hepatotoxicity of Shengshouwu and Zhiheshouwu in vitro and in vivo, and their clinical settings and adverse drug reactions（ADR） were summarized, analyzed and critically reviewed. In bench research, both drug forms had effects against nonalcoholic fatty liver disease, oxidation, fibrosis, cirrhosis, and liver cancer. Clinically, Heshouwu was used for treating fatty liver disease（FLD）, hyperlipidemia, cirrhosis and hepatitis B. In contrast, both drug forms could lead to drug-induced liver injury and even death in vitro, in vivo and in clinical settings. In addition, active components of both drug forms had hepatic benefits and toxicity in interaction with emodin, physcion, and probably 2,3,5,4’-tetrahydroxy-stilbene-2-O-beta-dglucoside（TSG）. In conclusion, Heshouwu exhibited both hepatoprotection and hepatotoxicity. It is essential to evaluate the advantages and disadvantages when Heshouwu is in clinical use. The study was financially supported by the Young Scientist Innovation Team Project of Hubei Colleges（T201510）;the Hubei Province Health and Family Planning Scientific Research Project（WJ2017 Z023）;the Open Project of Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine（WDCM001）;the Key Discipline Project of Hubei University of Medicine and the Foundation for Innovative Research Team of Hubei University of Medicine（2014 CXG03）;the Key Discipline Project of Hubei Province（2014 XKJSXJ18）.